Clinical trials: ANGIOEDEMA
Hereditary Angioedema (HAE), Angioedema
Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent angioedema attacks.
- Trial name
- NCT04583007
- Testing
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Where
- 20 sites in United States, Canada and 3 more
- Sponsor
- Shire
Angioedema
Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
This study aims to describe quality of life in hereditary or acquired non drug-related bradykinin-mediated angioedema patients, using validated questionnaires
- Trial name
- QUALANGIO (NCT03240991)
- Testing
- Quality of life
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hereditary Angioedema
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
The study objective was to describe the pharmacokinetics (PK) of one or two doses of C1 esterase inhibitor (C1INH-nf) in hereditary angioedema (HAE) subjects who were not experiencing an HAE attack.
- Trial name
- NCT00432510
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shire
Angioedemas, Hereditary
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina
The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice. This study is about collecting data only.
- Trial name
- NCT04955964
- Where
- Argentina
- Volunteers
- 48 people
- Sponsor
- Takeda
Urticaria, Angioedema
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
This clinical study was designed based on our hypothesis that vitamin D plays an important role in chronic urticaria and that high dose supplementation with vitamin D in subjects with chronic urticaria will improve clinical…
- Conditions
- Urticaria, Angioedema, Hives, Swelling
- Trial name
- NCT01371877
- Testing
- High Dose Vitamin D3, Low Dose Vitamin D3
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Nebraska
Hereditary Angioedema (HAE)
A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People
This study intends to gather information on HAE attack symptoms, how often the attacks occur, and the number of times treatment is required to manage the attacks in Korean people over a period of up to 11 months.
- Trial name
- SPEAKUP (NCT06587464)
- Testing
- No Intervention
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Takeda
Hereditary Angioedema, HAE
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.
- Trial name
- APeX-A (NCT04933721)
- Testing
- berotralstat
- Where
- 16 sites in Canada, Czechia and 9 more
- Volunteers
- 139 people
- Sponsor
- BioCryst Pharmaceuticals
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Angio Edema
Evaluation of New Markers in Type 3 Angioedema
Angioedema is a common condition, with multiple etiologies. Type 3 angioedema is caused by an increase in kininogenase activity responsible for an increased production of bradykinin.
- Trial name
- NCT03917680
- Testing
- Factor XII dosage, p.Thr328Lys mutation detection, Videocapillaroscopy
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brugmann University Hospital
Hereditary Angioedema (HAE)
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)
The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr® (icatibant) and/or Cinryze®…
- Trial name
- NCT01034969
- Where
- 74 sites in Australia, Austria and 12 more
- Volunteers
- 1,761 people
- Sponsor
- Shire
Expanded Access for Hereditary Angioedema (HAE)
Approval for access is solely at CSL Behring's discretion and the following criteria must be met for CSL Behring to consider access to experimental or unlicensed product: The patient has an unmet medical need that is…
- Trial name
- NCT03177005
- Testing
- CSL830
- Sponsor
- Joshua S. Jacobs, MD
Hypertension, Diabetes Type 2
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme…
- Trial name
- NCT01413542
- Testing
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Genetic Disorders
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary…
- Trial name
- NCT00261053
- Testing
- i.v. recombinant human C1 inhibitor
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Pharming Technologies B.V.
Chronic Spontaneous Urticaria
STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema
Chronic spontaneous urticaria and angioedema (CSUA) is a disease of the skin characterised by hives, swellings or both that last longer than 6 weeks.
- Trial name
- STOP CSUA (NCT05169645)
- Testing
- Physical activity monitoring - Symptom monitoring
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- St. James's Hospital, Ireland
Hereditary Angioedema (HAE)
A Survey of Lanadelumab in Participants With Hereditary Angioedema
This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics…
- Trial name
- NCT05397431
- Testing
- Lanadelumab
- Where
- Japan
- Volunteers
- 155 people
- Sponsor
- Takeda
Hereditary Angioedema
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
The main aim of the study is to check for side effects from icatibant in children and teenagers with hereditary angioedema (HAE).
- Trial name
- NCT04654351
- Testing
- TAK-667
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Takeda
Hereditary Angioedema
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
- Trial name
- NCT07654829
- Testing
- KVD900 600 mg
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema (HAE), Suicidal Ideation
Suicide Ideation in Hereditary Angioedema
This study focuses on patients with Hereditary Angioedema (HAE) to better understand how mental health affects overall well-being.
- Conditions
- Hereditary Angioedema (HAE), Suicidal Ideation, Cardiovascular Risk
- Trial name
- HAE-SAFE (NCT06811467)
- Volunteers
- 100 people
- Sponsor
- Ivan Cherrez Ojeda
Hereditary Angioedema (HAE)
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema…
- Trial name
- NCT01756157
- Testing
- CINRYZE with rHuPH20
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 47 people
- Sponsor
- Shire
Hereditary Angioedema
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and…
- Trial name
- NCT01397864
- Testing
- rhC1INH or pdC1INH
- Where
- 17 sites in Bulgaria, Croatia and 11 more
- Volunteers
- 181 people
- Sponsor
- Pharming Technologies B.V.